Analyzing Cost of Revenue: AbbVie Inc. and ADMA Biologics, Inc.

Analyzing Cost of Revenue: AbbVie Inc. vs. ADMA Biologics, Inc.

In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. This analysis compares the cost of revenue for AbbVie Inc. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, AbbVie Inc. consistently outpaced ADMA Biologics, with its cost of revenue growing by approximately 360%, reaching a peak in 2023. In contrast, ADMA Biologics saw a staggering increase of over 4,400%, reflecting its rapid expansion and scaling efforts. Notably, AbbVie's cost of revenue in 2023 was nearly 120 times that of ADMA Biologics, highlighting the significant scale difference between the two companies. This data underscores the diverse strategies and growth trajectories within the pharmaceutical sector, offering valuable insights for investors and industry analysts alike.